Reviewing Cytosorbents Corporation (CTSO) and Koninklijke Philips N.V. (PHG)
Cytosorbents Corporation (NASDAQ: CTSO) and Koninklijke Philips N.V. (NYSE:PHG) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.
Valuation & Earnings
This table compares Cytosorbents Corporation and Koninklijke Philips N.V.’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Cytosorbents Corporation||$12.18 million||12.70||-$10.41 million||($0.36)||-15.28|
|Koninklijke Philips N.V.||$29.77 billion||1.31||$3.79 billion||$1.74||23.96|
Koninklijke Philips N.V. has higher revenue and earnings than Cytosorbents Corporation. Cytosorbents Corporation is trading at a lower price-to-earnings ratio than Koninklijke Philips N.V., indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
6.9% of Cytosorbents Corporation shares are held by institutional investors. Comparatively, 7.6% of Koninklijke Philips N.V. shares are held by institutional investors. 5.6% of Cytosorbents Corporation shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Koninklijke Philips N.V. pays an annual dividend of $0.73 per share and has a dividend yield of 1.8%. Cytosorbents Corporation does not pay a dividend. Koninklijke Philips N.V. pays out 42.0% of its earnings in the form of a dividend. Cytosorbents Corporation has increased its dividend for 4 consecutive years.
Risk & Volatility
Cytosorbents Corporation has a beta of -0.56, meaning that its share price is 156% less volatile than the S&P 500. Comparatively, Koninklijke Philips N.V. has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Cytosorbents Corporation and Koninklijke Philips N.V., as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Koninklijke Philips N.V.||0||5||5||0||2.50|
Cytosorbents Corporation presently has a consensus price target of $12.71, indicating a potential upside of 131.06%. Koninklijke Philips N.V. has a consensus price target of $33.50, indicating a potential downside of 19.64%. Given Cytosorbents Corporation’s stronger consensus rating and higher possible upside, equities analysts plainly believe Cytosorbents Corporation is more favorable than Koninklijke Philips N.V..
This table compares Cytosorbents Corporation and Koninklijke Philips N.V.’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Koninklijke Philips N.V.||6.39%||8.92%||3.85%|
Koninklijke Philips N.V. beats Cytosorbents Corporation on 9 of the 16 factors compared between the two stocks.
Cytosorbents Corporation Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.
Koninklijke Philips N.V. Company Profile
Koninklijke Philips N.V. is a health technology company. The Company’s segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, and Lighting. The Company’s Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease. The Company’s Diagnosis & Treatment businesses segment delivers precision medicine and treatment, and therapy. The Company’s Connected Care & Health Informatics businesses segment provides consumers, care givers and clinicians with digital solutions that facilitate care by enabling precision medicine and population health management. The Company’s Philips Lighting is engaged in the development, manufacture and application of lighting products, systems and services. The Company is the parent company of the Philips Group (Philips).
Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.